Akcea Retains Rights to AKCEA-APOCIII-LRx

    NEXT STORY
    European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
    PREV STORY
    ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Dynavax to Host Third Quarter 2018 Financial Results Conference Call

    BERKELEY, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today ...

    author_avatar
    NASDAQ Market News

    Arrayit Corporation Signs Allergy Testing Contracts with a Nationwide Consortium of Medical Clinics

    author_avatar
    NASDAQ Market News

    Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients

    author_avatar
    NASDAQ Market News